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Vinculin regulates a variety of cellular functions partly through stabilization of tumor 
suppressor PTEN. In order to study the role of vinculin in tumor progression other than 
PTEN stabilization, vinculin was knocked down in PTEN-deficient squamous cell carcinoma 
HSC-4 cells. Knockdown of vinculin induced phenotypical change by reducing cell-cell and 
cell-extracellular matrix adhesions, and enhanced MT1-MMP expression at transcription 
level and subsequent cell migration. Up-regulation of MT1-MMP transcription by vinculin 
knockdown was abrogated by ERK inhibition. These results suggest that vinculin negatively 








A cellular adhesiveness, including cell-cell and cell-extracellular matrix (ECM) adhesions, 
correlates with invasive and metastatic phenotype of cancer. Viculin has been implicated as 
an inhibitor of cell migration, as it enhanced cellular adhesiveness [1-4]. Loss or reduced 
expression of vinculin is related to the metastatic potential of squamous cell carcinomas 
(SCC), although in situ SCC exhibits high level expression of vinculin [5]. The role of 
vinculin in suppression of the malignant phenotype of SCC still remains to be solved. 
Vinculin is a well-known component of cell-ECM adhesions by interacting with several 
focal adhesion proteins such as talin, paxillin, tensin, VASP, zyxin, vinexin, filamin, α-actinin, 
actin and focal adhesion kinase (FAK) either directly or indirectly [6]. It possesses tumor 
suppressive functions. Studies using F9 embryonic mouse carcinoma cells showed that 
vinculin knockout cells exhibit more rounded phenotype, less spreading, smaller focal 
adhesions and increased motility compared with wild type [1,2]. Mouse embryonic 
fibroblasts from vinculin knockout mouse also showed decreased cell-matrix adhesion, 
increased motility and FAK phosphorylation compared with wild-type cells [7]. Vinculin 
competes with paxillin for binding to FAK, which modulates extracellular signal–regulated 
kinase (ERK) activation in the downstream of FAK/paxillin [8].  
Vinculin also localizes at and modulates cell-cell adhesions [6,9]. It binds to α- and 
β-catenin, which bind to one another and regulate cell-cell adhesion by interacting with 
cadherin adhesion receptors. The interaction between vinculin and catenins facilitates the 
stability of E-cadherin adhesions [10,11]. This enhanced cadherin adhesion stabilize a 
well-known tumor suppressor phosphatase and tensin homolog deleted on chromosomal 10 
(PTEN) by interfering with ubiquitin-mediated proteolytic degradation of PTEN, which 
results from the binding of vinculin with membrane-associated guanylate-kinase inverted 
2/β–catenin complex [12]. Loss of vinculin attenuates the protein level of PTEN, which is 
recovered by ectopic expression of vinculin. PTEN stabilizes E-cadherin adhesions, and is 
often deleted in cancers [13]. Consequently, vinculin may facilitate tumor suppressive 
function of E-cadherin and PTEN.  
Membrane-type 1 matrix metalloproteinase (MT1-MMP) is considered to play a 
significant role in tumor progression, as its expression correlates most closely with the 
invasive phenotype of human tumors among MMPs and the inhibition of MT1-MMP 
suppresses tumor cell invasion both in vitro and in vivo [14]. MT1-MMP was originally 
identified as a tumor-specific MMP-2 activator [15]. It activates MMP-2 and -13 and 
degrades a wide range of ECM components, including type I, II, III collagen, laminins, and 
fibronectin. This enzyme also processes and interacts with membrane-tethered proteins such 
as integrins and CD44 [14]. The activity of MT1-MMP is up-regulated by ERK [16,17] and 
down-regulated by PTEN [18]. 
The aim of this study is to understand how vinculin regulates motility and invasiveness of 
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SCC cells that lacks PTEN. We analyzed the effect of vinculin knockdown on MT1-MMP 
activity and invasion of SCC cells deficient in PTEN. 
 
2. Materials and methods 
 
2.1.Cell culture and reagents  
 
Human oral SCC HSC-3 and HSC-4 cells were obtained from the Health Science 
Research Bank (Osaka, Japan). Cells were maintained in Dulbecco’s modified Eagle’s 
medium (DMEM) supplemented with 10% fetal bovine serum (FBS). The reagents used were 
type I collagen (Nitta Gelatin, Osaka, Japan); MEK inhibitor (PD98059) (Merck Millipore, 
Temecula, CA, USA). A synthetic MMP inhibitor (BB94) was a kind gift from the Kotobuki 
Pharmaceutical Co., Ltd. (Nagano, Japan). An anti-MT1-MMP antibody was gifted by 
Dai-ichi fine chemicals (Toyama, Japan). The immunological reagents used were 
anti-E-cadherin, anti--catenin, anti-ERK2, and anti-paxillin antibodies (BD Biosciences, 
Bedford, MA, USA); anti-phospho-p44/42 MAPK and anti-PTEN antibodies (Cell Signaling 
Technology, Danvers, MA, USA); anti--tubulin and anti-vinculin antibodies (Sigma-Aldrich, 
St Louis, MO, USA); an anti-vinculin antibody (Santa Cruz Biotechnology, Santa Cruz, CA, 
USA); an anti-p53 antibody (Merck Millipore); Rhodamine-labeled phalloidin, Hoechst 
33342, and Alexa Fluor-labeled secondary antibodies (Molecular Probes, Eugene, OR, USA). 
 
2.2.Small interfering RNA (siRNA)-mediated protein knockdown  
 
A siRNA for negative control was purchased from Qiagen (Valencia, CA, USA). The 
siRNA sequences used here were: mt1-mmp, 5’-GCGAUGAAGUCUUCACUUATT; 
vinculin-1, 5’-GGCAUAGAGGAAGCUUUAATT; vinculin-3, 
5’-GCCAAGCAGUGCACAGAUATT. Cells were transfected with 20 nM of siRNA 
duplexes in Opti-MEM (Invitrogen, Carlsbad, CA, USA) using Lipofectamine RNAi MAX 




Cells were washed with phosphate-buffered saline (PBS), and homogenized in SDS lysis 
buffer containing 10 mM Tris-HCl (pH 7.5), 100 mM NaCl, 5 mM EDTA, 2 mM Na3VO4, 2 
mM NaF, and 1% SDS. Protein concentration was determined using BCA assay (Pierce, 
Thermo Scientific, Rockford, IL, USA). Samples were separated by electrophoresis on 
SDS-polyacrylamide gels and transferred onto nitrocellulose membranes. Membranes were 
reacted with the indicated antibodies. The signal was monitored using a Li-COR Odyssey IR 
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imaging system (Lincoln, NE, USA). 
 
2.4.Immunofluorescence staining  
 
Cells grown on the coverslips were washed with PBS, fixed with 4% paraformaldehyde, 
permeabilized with 0.5% Triton X-100, and reacted with indicated antibodies. Samples were 
observed by confocal laser scanning microscopy LSM510 (Carl Zeiss, Jena, Germany).  
 
2.5.Real-time PCR quantification  
 
cDNA were generated from total RNA using a QuantiTect reverse transcription kit 
(Quiagen). Real-time quantitative PCR experiments were carried out using the following 
PCR primers for mt1-mmp: forward (5’-GGAATAACCAAGTGATGGATGG) and reverse 
(5’-TTGTTTCCACGGAAGAAGTAGG). Hs_GAPDH_1_SG QuantiTect Primer (Qiagen) 




HSC-4 cells transfected with siRNA were replated on 35-mm dishes coated with 300 
g/ml of type I collagen in 10% FBS/DMEM with or without BB94 (10 μM). Two hour after 
replating, cell migration was monitored using an Cultured Cell Monitoring System (Astec, 
Fukuoka, Japan) for 6 h. Video images were collected at 20-min intervals, digitized, and 




3.1. Vinculin knockdown promotes MT1-MMP-mediated proMMP-2 activation 
 
Loss of vinculin promotes ubiquitin-mediated proteolysis of PTEN, which regulates a 
variety of proteins as a tumor suppressor. In order to study the cellular function of vinculin 
other than PTEN stabilization in SCC, we employed SCC HSC-4 cells that lacked PTEN 
expression in this study (Fig. 1A). Consistent with previous studies [1-4], vinculin 
knockdown cells showed lower cell-cell and cell-ECM adhesions compared with 
mock-transfected HSC-4 cells (Fig. 1B). Cell-cell adhesions supported by β-catenin were 
reduced in vinculin knockdown cells; cell-ECM adhesion stained by anti-paxillin antibody 
was poor-organized and smaller in vinculin-depleted cells than mock-transfected cells. Next, 
the effect of vinculin knockdown on MT1-MMP-mediated proMMP-2 activation was 
examined. HSC-4 cells expressed endogenous MT1-MMP, and thereby induced the activation 
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of proMMP-2, which was suppressed by the transfection of siRNA for MT1-MMP (Fig. 1C). 
Enhanced proMMP-2 activation in vinculin-knockdowned cells was completely inhibited by 
knockdown of MT1-MMP. In parallel with proMMP-2 activation, the protein level of 
MT1-MMP was increased in vinculin-depleted cells. The expression level of MT1-MMP 
mRNA examined by real-time PCR quantification was up-regulated by 2 to 2.5-fold in 
vinculin knockdown cells compared with mock-transfected cells (Fig. 1D). These results 
indicate that knockdown of vinculin up-regulates the expression of MT1-MMP at 
transcription level, resulting in the promotion of MT1-MMP activity including proMMP-2 
activation.  
 
3.2. Up-regulation of MT1-MMP by vinculin knockdown requires ERK 
 
Vinculin knockdown induces the association between FAK and paxillin, which results in 
the increase of ERK activation [8]. The effect of MEK/ERK inhibition on MT1-MMP activity 
stimulated by vinculin knockdown was tested. Treatment with MEK inhibitor PD98059 
repressed both ERK activation and MT1-MMP-mediated proMMP-2 activation in 
vinculin-depleted HSC-4 cells (Fig. 2A). In parallel with reduced proMMP-2 activation, 
up-regulation of MT1-MMP mRNA was suppressed by PD98059 (Fig. 2B). These results 
suggest that ERK activation by FAK/paxillin is required for up-regulation of MT1-MMP in 
vinculin-depleted HSC-4 cells. 
 
3.3. Vinculin suppresses cell motility on collagen 
 
Cell migration is stimulated by facilitating focal adhesion turnover through ECM 
degradation by MT1-MMP [14-16]. Then, we examined whether vinculin knockdown 
promotes the cell motility on type I collagen (Fig. 3A). The time lapse analysis of vinculin 
knockdown cells showed that vinculin-depleted cells migrated a longer distance than 
mock-transfected cells on type I collagen, which was suppressed by treatment with MMP 
inhibitor BB94 (Fig. 3B). On type I collagen, treatment with BB94 attenuated both 
MT1-MMP-mediated proMMP-2 activation and ERK activation in vinculin-depleted HSC-4 
cells (Fig. 3C). These results show that MT1-MMP activity stimulates migration and ERK 




Here we demonstrated that vinculin knockdown in SCC induced phenotypical change by 
reducing cell-cell and cell-ECM adhesions and stimulated MT1-MMP expression, resulting in 
enhanced cell migration on type I collagen. Vincuin interferes with the activation of 
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FAK/Paxillin pathway [8], and augments PTEN stability [12]. PTEN inhibits cell surface 
expression of MT1-MMP, resulting in the reduction of MT1-MMP activity [18]. As HSC-4 
cells used in this study lack PTEN expression (Fig. 1), vinculin knockdown may induce 
MT1-MMP transcription through the activation of FAK/Paxillin/ERK pathway without 
involvement of PTEN reduction. As MT1-MMP activity is up-regulated by ERK [16,17], 
treatment of vinculin-knockdown cells with MEK inhibitor PD98059 abrogated MT1-MMP 
induction (Fig. 2).  
Pericellular collagenolysis caused by up-regulated MT1-MMP through vinculin 
knockdown further activates FAK/Paxillin/ERK pathway, and induces cell migration on type 
I collagen (Fig. 3). The reduction of cellular adhesiveness by vinculin knockdown may also 
contribute to migration of HSC-4 cells. Both of MT1-MMP and paxillin are required for 
proliferation of HSC-4 cells during collagen gel culture [19]. Vinculin expression may also 
affect cell proliferation through modulation of the FAK-paxillin interaction and MT1-MMP 
expression. 
Knockout of vinculin in F9 embryonic mouse carcinoma cells and mouse embryonic 
fibroblasts show increased not only cell motility but also survival by activating 
FAK/Paxillin/ERK pathway [8,20]. Recent studies have demonstrated that MT1-MMP 
protects cancer cells from apoptosis induced by collagen gel culture [21]. HSC-4 cells used 
here express mutant form of p53-R248Q [22] and lack the expression of PTEN (Fig. 1). 
MT1-MMP may facilitate further HSC-4 cell survival induced by vinculin knockdown.  
The loss of vinculin links advanced poor prognosis in cancer patients [5,23,24]. Present 
findings revealed that vinculin is one of key molecules controlling SCC progression through 
FAK/Paxillin/ERK pathway and thereby MT1-MMP expression.  
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Fig. 1. Vinculin knockdown promotes MT1-MMP-mediated proMMP-2 activation. (A) Cell 
lysates from either HSC-3 or HSC-4 cells were analyzed by immunoblotting using 
MT1-MMP (MT1), anti-PTEN, anti-E-cadherin (Ecad), anti-p53 or anti-tubulin antibodies. 
(B) HSC-4 cells were cultured on glass coverslips, and transfected with siRNA for control 
(siScr) or vinculin (siVin1) for 48 h. The cells were analyzed by immunofluorescence 
staining using anti-β-catenin (βcat) or anti-paxillin antibodies, Rhodamine-phalloidin 
(F-actin), and Hoechst 33342 (Nuclei). Scale bars are 20 μm. (C) HSC-4 cells were 
transfected with siRNA for either control or vinculin (siVin1 or siVin3) plus siRNA for 
MT1-MMP (siMT1). The conditioned media were analyzed by gelatin zymography, and cells 
lysates were analyzed by immunoblotting using anti-MT1-MMP, anti-vinculin or anti-tubulin 
antibodies. (D) HSC-4 cells were transfected with siRNA for either control or vinculin 
(siVin1 or siVin3) and mRNA was prepared from these cells. Quantitative RT-PCR for 
mRNA expression of MT1-MMP was performed as described in “Section 2”. Expressions of 
MT1-MMP mRNA are normalized to that of cells transfected with siRNA for control. The 
error bars are standard deviations of the mean values obtained from three independent 
experiments. *, p < 0.05. 
 
Fig.2. Up-regulation of MT1-MMP by vinculin knockdown requires ERK activation. (A) 
HSC-4 cells were transfected with siRNA for either control or vinculin (siVin1 or siVin3) for 
48 h. After washing, cells were cultured in the absence or presence of PD98059 (25 μM) for 
24 h. The conditioned media were analyzed by gelatin zymography, and cells lysates were 
analyzed by immunoblotting using anti-phospho-p44/42 MAP kinase (pERK), anti-ERK2, 
anti-vinculin, or anti-tubulin antibodies. (B) Alternatively, mRNA was prepared from these 
cells, and quantitative RT-PCR for mRNA level of MT1-MMP was performed. Expressions 
of MT1-MMP mRNA are normalized to that of cells transfected with siRNA for control in 
the absence of PD98059. The error bars are standard deviations of the mean values obtained 
from three independent experiments. *, p < 0.05. 
 
Fig.3. Vinculin knockdown promotes cell motility on collagen. HSC-4 cells were 
transfected with siRNA for either control or vinculin for 48 h. The cells were replated onto 
collagen-coated dishes in the absence or presence of BB94 (10 μM) and cell motility was 
monitored for 6 h. Tracks of migrating cells were collected, digitized, and analyzed using 
Image J software. (A) Tracks of migrating cells at 60-min intervals. Scale bars are 10 μm. (B) 
Migrating distance of individual cells were determined by individual tracking of > 20 cells 
pooled from three independent experiments. Data show the percentage of migrating cells for 
the different migrating distances. Columns, mean; bars, SE. (C) HSC-4 cells were transfected 
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with siRNA for either control or vinculin and were replated onto collagen-coated dishes in the 
absence or presence of BB94 for 24 h. The conditioned media were analyzed by gelatin 
zymography, and cells lysates were analyzed by immunoblotting using anti-vinculin, 
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